Skip to main content

Sue Pandey, Nancy Pecota, Gianfranco DeFeo, Linda Buck, Nanogen, Prodesse

Premium

People in the News

Sue Pandey has been named vice president of commercial operations at NuGen Technologies, the San Carlos, Calif.-based company said last week.

Pandey most recently served as global head of sales at GE Healthcare, where she was responsible for managing its CodeLink operation. Pandey holds a PhD in chemistry from the University of California, Irvine, and an MBA from Pepperdine University.

NuGen also named Nancy Pecota to the position of chief financial officer and Gianfranco DeFeo as the firm's new senior director of customer solutions.

Pecota previously served as vice president of finance and administration at Signature Bioscience and as a senior director of finance and accounting at Aclara BioSciences. She holds a BSc in economics from San Jose State University.

DeFeo previously worked at Applied Biosystems and Affymetrix. Most recently, he managed the global technical support organization at Quantum Dot. DeFeo holds a PhD from the University of California, Los Angeles.


DeCode Genetics named Linda Buck to its board of directors, the Reykjavik-Iceland based company said last week.

Buck received a Nobel Prize in physiology or medicine in 2004 for her discoveries on the workings of the olfactory system. She is the Associate Director of the Basic Sciences Division at the Fred Hutchinson Cancer Research Center in Seattle, Wash., and a Howard Hughes Medical Institute investigator. She also is an affiliate professor of physiology and biophysics at the University of Washington.

Prior to her current positions, Buck was a professor of neurobiology at Harvard Medical School and received her PhD in immunology from the University of Texas Southwestern Medical Center at Dallas.

 

New Product Watch

Nanogen this week launched two molecular reagent products to detect genetic sequences for respiratory viral pathogens.

The company now offers its NGEN RVA Analyte Specific Reagent product that it claims can be used to develop and validate assays to detect the sequences of and differentiates among influenza A and B, respiratory syncytial virus and parainfluenza 1, 2, and 3.

The RVA product was co-developed with Prodesse and has been CE marked in Europe, Nanogen said. It added that the ASR is "available in the United States as an ASR for which analytical and performance characteristics are not established."

Nanogen also launched its MGB Eclipse Flu A/B Primer and Probe Set, which it claims can provide melt curve analysis that enables differentiation of two viral strains for each sample tested.

The San Diego-based company also said both sets and reagents target a nucleic acid sequence also found in the H5N1 strain of the influenza A virus, also known as avian flu.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.